2024 HCPCS Code C9076
Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
TAGS: lisocabtagene viable preparation leukapheresis autologous therapeutic million
Notice | HCPCS C9076 terminated on September 30, 2021. |
Short Description | Lisocabtagene car pos t |
HCPCS Coverage Code | D - Special coverage instructions apply |
HCPCS Action Code | N - No maintenance for this code |
HCPCS Action Effective Date | October 01, 2021 |
HCPCS Code Added Date | July 01, 2021 |
HCPCS Pricing Indicator Code | 53 - Statute |
HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
HCPCS Coverage Issues Manual Reference Section Number | |
HCPCS Type Of Service Code | 9 - Other medical items or services |
HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- C9028 - Inj. inotuzumab ozogamicin
- C9029 - Injection, guselkumab
- C9030 - Inj copanlisib
- C9031 - Lutetium lu 177 dotatate, tx
- C9032 - Voretigene neparvovec-rzyl
- C9033 - Inj, akynzeo
- C9034 - Injection, dexamethasone 9%
- C9035 - Injection, aristada initio
- C9036 - Injection, patisiran
- C9037 - Injection, risperidone
- C9038 - Inj mogamulizumab-kpkc
- C9039 - Injection, plazomicin
- C9040 - Injection, fremanezumab-vfrm
- C9041 - Inj, coagulation factor xa
- C9042 - Inj., belrapzo 1 mg
- C9043 - Injection, levoleucovorin
- C9044 - Injection, cemiplimab-rwlc
- C9045 - Moxetumomab pasudotox-tdfk
- C9046 - Cocaine hcl nasal (goprelto)
- C9047 - Injection, caplacizumab-yhdp